Combination chemotherapy is the mainstay of treatment for acute lymphoblastic leukemia (ALL). The Hyper-CVAD regimen was developed in 1992 at MD Anderson Cancer Center and has since become a standard of care option for adult patients with ALL. Since its conception, a number of modifications have been implemented to customize the regimen for different patient populations and safely incorporate novel therapies without compromising tolerability. We aim to review the evolution of the Hyper-CVAD regimen over the past 3 decades, focusing on clinical pearls, as well as future directions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clml.2023.01.013 | DOI Listing |
Publication Analysis
Top Keywords
hyper-cvad regimen
8
soho state
4
state art
4
art updates
4
updates questions
4
questions hyper-cvad
4
hyper-cvad 2022
4
2022 lessons
4
lessons learned
4
learned approaches
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!